妊娠期非甾体抗炎药暴露与儿童慢性肾脏病风险
孕中期和孕晚期风险升高,特定NSAID与不同孕期风险相关。
要点
- 妊娠期NSAID暴露与儿童CKD风险轻度升高相关(wHR 1.10,95%CI 1.05-1.15)。
- 同胞比较未发现NSAID与胎儿肾毒性相关。
- 孕中期和孕晚期暴露风险升高,特定NSAID与不同孕期风险相关。
核心结论
- 妊娠期NSAID暴露与儿童CKD风险轻度升高相关,但同胞比较未显示 substantial 增加。
- 需谨慎处方妊娠期NSAID,尤其特定药物和孕期。
研究设计与样本
- 全国性队列研究,纳入2007年1月1日至2017年12月31日台湾地区1 025 255名活产儿,随访至2021年12月31日。
- 暴露为末次月经至分娩期间母亲NSAID处方,主要结局为儿童CKD。
- 采用Cox比例风险回归模型加稳定逆概率治疗加权(wHR)和稳健夹心估计器,调整新生儿特征。
主要发现
- 163 516名(24.0%)单胎儿童的母亲孕期至少使用1次NSAID。
- 妊娠期NSAID暴露与儿童CKD风险升高相关(wHR 1.10;95%CI 1.05-1.15)。
- 同胞比较未观察到NSAID使用与胎儿肾毒性关联。
- 单胎儿童中,孕中期暴露风险升高(wHR 1.19;95%CI 1.11-1.28),孕晚期暴露风险升高(wHR 1.12;95%CI 1.03-1.22)。
- 特定NSAID暴露与CKD风险升高相关:孕早期吲哚美辛(wHR 1.69;95%CI 1.10-2.60)和酮咯酸(wHR 1.28;95%CI 1.01-1.62),孕中期双氯芬酸(wHR 1.27;95%CI 1.13-1.42)和甲芬那酸(wHR 1.29;95%CI 1.15-1.46),孕晚期布洛芬(wHR 1.34;95%CI 1.07-1.68)。
临床怎么用
- 妊娠期处方NSAID需谨慎,尤其孕早期避免吲哚美辛和酮咯酸,孕中期避免甲芬那酸和双氯芬酸,孕晚期避免布洛芬。
- 对妊娠期NSAID暴露儿童,应关注肾脏安全,必要时进行肾功能监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Gestational exposure to nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of adverse fetal kidney outcomes. However, details regarding timing, specific NSAIDs, and long-term childhood kidney outcomes are limited. OBJECTIVE: To evaluate the association between gestational exposure to NSAIDs and the risk of chronic kidney disease (CKD) in childhood. DESIGN, SETTING, AND PARTICIPANTS: This national cohort study assessed 1 025 255 children born alive in Taiwan from January 1, 2007, to December 31, 2017, with follow-up until December 31, 2021. Children without valid maternal-child linkage and with incomplete birth information were excluded. Data analysis was performed from November 30, 2023, to April 30, 2024. EXPOSURE: Maternal prescriptions for NSAIDs from the last menstrual period to birth. MAIN OUTCOMES AND MEASURES: The main outcome was childhood CKD, including congenital anomalies of the kidney and urinary tract and other kidney diseases. Cox proportional hazards regression models with stabilized inverse probability of treatment weighting (weighted hazard ratio [wHR]) and a robust sandwich estimator were used to estimate the relative risk of NSAID exposure in pregnancy, adjusted for newborn characteristics. RESULTS: This study included 163 516 singleton-born children (24.0%) whose mothers (mean [SD] age at birth of child, 31.25 [4.92] years) used at least 1 dispensing of an NSAID during pregnancy. Gestational NSAID exposure was significantly associated with a higher risk of childhood CKD (wHR, 1.10; 95% CI, 1.05-1.15). No association was observed between NSAID use and fetal nephrotoxicity in sibling comparisons. Elevated risks were revealed for exposure during the second trimester (wHR, 1.19; 95% CI, 1.11-1.28) and the third trimester (wHR, 1.12; 95% CI, 1.03-1.22) in singleton-born children. Specific NSAID exposures associated with higher CKD risk included indomethacin (wHR, 1.69; 95% CI, 1.10-2.60) and ketorolac (wHR, 1.28; 95% CI, 1.01-1.62) in the first trimester, diclofenac (wHR, 1.27; 95% CI, 1.13-1.42) and mefenamic acid (wHR, 1.29; 95% CI, 1.15-1.46) in the second trimester, and ibuprofen (wHR, 1.34; 95% CI, 1.07-1.68) in the third trimester. CONCLUSIONS AND RELEVANCE: In this study, gestational exposure to NSAIDs was not associated with a substantial increase in the risk of childhood CKD when comparing between siblings. However, the findings underscore the need for caution when prescribing NSAIDs during pregnancy, particularly indomethacin and ketorolac in the first trimester, mefenamic acid and diclofenac in the second trimester, and ibuprofen in the third trimester, to ensure the safety of the offspring's kidneys.
引用
- Tain YL, Li LC, Kuo HC, et al. Gestational Exposure to Nonsteroidal Anti-Inflammatory Drugs and Risk of Chronic Kidney Disease in Childhood. JAMA Pediatr. 2025. PMID: 39714827. doi:10.1001/jamapediatrics.2024.4409
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。